The purpose of this amendment was to: ● Update the Treatment Period to add: "Prophylactic use of rescue analgesics (i.e., on a standing basis or for prevention of pain) for endometriosis-associated pain is not permitted during the study (from Day 1 of the Treatment Period through Month 6 of the Post-treatment Follow-up Period)." Subjects were allowed the use of permitted analgesic rescue therapy on an as needed basis. ● Update Selection of Study Population to split the combined Exclusion Criterion 6 into 2 separate criteria to clarify malignancy Criterion 6 and neuropsychiatric Criterion 7. ● Update Prohibited Therapy to remove prescription amphetamine, or amphetamine-like drugs, and to add cannabinoids inclusive of any marijuana use, as prohibited medications. ● Update Permitted Rescue Therapy to remove Tramadol 50 mg. ● Update Efficacy, Pharmacokinetic, Pharmacodynamic and Safety Assessments as follows: - Efficacy and Safety Measurements Assessed to provide clarifications and incorporate applicable changes within the body text of the protocol. - Increase the visit window from 4 to 5 days. - Update Medical/Social History to add a collection of documentation of drug abuse (licit or illicit) at Day 1. - Update Pap Test to add biopsy with colposcopy, and to clarify that both colposcopy and biopsy results should be discussed with the sponsor. - Update Study Procedures with a footnote to clarify 8-hour minimum fast for Clinical/Safety Laboratory Tests. - Update Clinical Laboratory Tests, to change "Any repeat testing must be approved" to "Any repeat testing should be approved by an AbbVie representative." - Update BMD to allow scans be performed within 5 days of scheduled visit ● Update Adverse Event Reporting to include a 24-hour hotline for the investigator to contact AbbVie on-call physician in emergency. ● Update Pregnancy to add "any" to clarify that outcome of any pregnancy should be collected ● Update Statistical Methods to clarify methods.

The purpose of this amendment was to: ● Remove fasting requirement on study drug administration ● Add requirement on use of calcium and vitamin D daily during the PTFU Period. ● Clarify that a brief physical examination is conducted only if there are reported symptoms. ● Instruct on use of the same modality consistently to measure body temperature. ● Clarify that subjects with a Pap diagnosis of atypical squamous cells of undetermined significance (ASC-US) with high risk human papillomavirus (HPV) or low-grade squamous intraepithelial lesion (LSIL) should undergo additional evaluation with colposcopy and biopsy, if applicable per local guidelines. ● Clarify that pregnancy testing applies to all subjects, whether exempted from use of a dual barrier non-hormonal contraception or not, and request that subjects attest on use of allowable contraception methods at every visit. ● Add requirement for DXA Scan at Month 6 in the PTFU Period for all subjects. ● Change the capacity of the collection tubes and the amount of serum collected from 4 mL to 3 mL. ● Add change from baseline in ECG to the safety variables. ● Clarify that temperature must be recorded each business day to document proper temperature of clinical supplies. ● Clarify that changes in BMD may be considered an AE if resulting in discontinuation from the study. ● Instruct sites to complete an SAE on the non-CRF forms and provide guidance when access to RAVE® is unavailable. ● Add specifics on time windows for analyses, referencing the SAP. ● Replace "nominal day" with "reference study day," and clarify window calculation for Month 1. ● Clarify that sensitivity analyses are done for the proportion of DYS and NMPP responders at Month 6. ● Remove the statement on "Subjects who discontinue for other reasons will be categorized according to LOCF." ● Add that information on responders will be based on the ROC thresholds calculated in Study M12-671. ● Specify which variable will be analyzed at EOT.